383 related articles for article (PubMed ID: 25384963)
1. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
[TBL] [Abstract][Full Text] [Related]
2. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
Sun B; Liu X; Gao Y; Li L; Dong Z
Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
[TBL] [Abstract][Full Text] [Related]
4. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
5. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
6. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Permuth-Wey J; Chen DT; Fulp WJ; Yoder SJ; Zhang Y; Georgeades C; Husain K; Centeno BA; Magliocco AM; Coppola D; Malafa M
Cancer Prev Res (Phila); 2015 Sep; 8(9):826-34. PubMed ID: 26314797
[TBL] [Abstract][Full Text] [Related]
7. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
8. miRNA-21 and miRNA-34a Are Potential Minimally Invasive Biomarkers for the Diagnosis of Pancreatic Ductal Adenocarcinoma.
Alemar B; Izetti P; Gregório C; Macedo GS; Castro MA; Osvaldt AB; Matte U; Ashton-Prolla P
Pancreas; 2016 Jan; 45(1):84-92. PubMed ID: 26262588
[TBL] [Abstract][Full Text] [Related]
9. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
Yu Q; Xu C; Yuan W; Wang C; Zhao P; Chen L; Ma J
Biomed Res Int; 2017; 2017():6495867. PubMed ID: 28466015
[No Abstract] [Full Text] [Related]
12. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
13. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
14. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer.
Takahashi K; Ota Y; Kogure T; Suzuki Y; Iwamoto H; Yamakita K; Kitano Y; Fujii S; Haneda M; Patel T; Ota T
Cancer Sci; 2020 Jan; 111(1):98-111. PubMed ID: 31715081
[TBL] [Abstract][Full Text] [Related]
15. An elevated expression of serum exosomal microRNA-191, - 21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker.
Goto T; Fujiya M; Konishi H; Sasajima J; Fujibayashi S; Hayashi A; Utsumi T; Sato H; Iwama T; Ijiri M; Sakatani A; Tanaka K; Nomura Y; Ueno N; Kashima S; Moriichi K; Mizukami Y; Kohgo Y; Okumura T
BMC Cancer; 2018 Jan; 18(1):116. PubMed ID: 29385987
[TBL] [Abstract][Full Text] [Related]
16. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis.
Zhuo M; Yuan C; Han T; Cui J; Jiao F; Wang L
BMC Cancer; 2018 Oct; 18(1):1032. PubMed ID: 30352575
[TBL] [Abstract][Full Text] [Related]
17. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
[TBL] [Abstract][Full Text] [Related]
19. Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
Komatsu S; Ichikawa D; Miyamae M; Kawaguchi T; Morimura R; Hirajima S; Okajima W; Ohashi T; Imamura T; Konishi H; Shiozaki A; Ikoma H; Okamoto K; Taniguchi H; Otsuji E
Expert Opin Biol Ther; 2015 Jun; 15(6):773-85. PubMed ID: 25819175
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs of the mir-17~92 cluster regulate multiple aspects of pancreatic tumor development and progression.
Quattrochi B; Gulvady A; Driscoll DR; Sano M; Klimstra DS; Turner CE; Lewis BC
Oncotarget; 2017 May; 8(22):35902-35918. PubMed ID: 28415794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
